Cellphire Therapeutics is committed to transforming hemostasis management with innovative products that fill critical gaps in the treatment of bleeding patients. Our lead clinical-stage candidate, Thrombosomes®, is an activated platelet-based hemostatic. The product is currently in a Phase 2 clinical trial in bleeding thrombocytopenic patients. Thrombosomes has also been given orphan drug designation for the treatment of Acute Radiation Sickness by the U.S. Food and Drug Administration.
Cellphire is identifying and developing other novel platelet-based therapies to address unmet needs. We’re researching transformative roles for platelets in targeted drug delivery, anti-thrombotic reversal, and regenerative medicine, among others.
To learn more about the thinking behind our science, click here.
Prior Phase 1 safety studies support all Thrombosomes indications.
Submission for approval for ARS would be under the Animal Rule; human Phase 1 studies provide safety data in support of the Animal Rule.